Penpulimab, anlotinib, and chemo before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (penpulimab, anlotinib, and chemotherapy) given before surgery to shrink esophageal cancer. It is for people with locally advanced cancer who have not had treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal cancer that has not spread to distant organs (stage II to IVA).
- You have not had any previous treatment for your esophageal cancer.
- You are in good enough health to be active (ECOG score 0 or 1).
- Your major organs (heart, lungs, liver, kidneys, bone marrow, thyroid) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs, a targeted therapy, and chemotherapy before surgery helps shrink esophageal tumors and improve outcomes. It might make surgery more effective for patients with resectable esophageal cancer.
This trial tests whether combining the immunotherapy drug tislelizumab with chemotherapy before and after surgery helps treat esophageal squamous cell cancer better than just surgery alone. It aims to shrink the tumor before surgery and reduce the chance of the cancer coming back afterward.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.